Диссертация (1140273), страница 28
Текст из файла (страница 28)
– P.198-208.46.Corpechot C., El Naggar A., Poujol-Robert A., Ziol M., Wendum D., Chazouillères O., et al.Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC //Hepatology. – 2006. – Vol.43. – №5. – P.1118-24.47.Corpechot C., Gaouar F., El Naggar A., Kemgang A., Wendum D., Poupon R., et al. Baselinevalues and changes in liver stiffness measured by transient elastography are associated withseverity of fibrosis and outcomes of patients with primary sclerosing cholangitis //Gastroenterology.
– 2014. – Vol.146. – №4. – P.970-9.48.Czaja A.J. Diagnosis and management of the overlap syndromes of autoimmune hepatitis //Can J Gastroenterol. – 2013. – Vol.27. – №7. – P.417-23.49.Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis, and management ofautoimmune hepatitis // Gastroenterology. – 2010.
– Vol.139. – №1. – P.58-72.50.De Alwis NMW, Day C.P. Non-alcoholic fatty liver: the mist gradually clear // J Hepatol –2008. – Vol.48. – Suppl(1). – P.S105–S112.51.Degos F., Perez P., Roche B., Mahmoudi A., Asselineau J., Voitot H., et al. Diagnosticaccuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: amulticenter prospective study (the FIBROSTIC study) // J Hepatol.
– 2010. – Vol.53. – №6. –P.1013–1021.52.Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronichepatitis: diagnosis, grading and staging // Hepatology. – 1994. – Vol.19. – №6. – P.1513-20.53.Duarte-Rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts forimproving accuracy in daily clinical practice // Ann Hepatol. – 2012. – Vol.11.
– №4. –Р.426-39.54.EASL Clinical Practice Guidelines: Autoimmune hepatitis. European Association for theStudy of the Liver // J Hepatol. – 2015. – Vol.63. – №4. – P.971-1004. 55.133 EASL Clinical Practice Guidelines: management of cholestatic liver diseases. EuropeanAssociation for the Study of the Liver // J Hepatol. – 2009. – Vol.51. – №2. – P.237-67.56.EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver diseaseseverityandprognosis.EuropeanAssociationforStudyofLiver;AsociacionLatinoamericana para el Estudio del Higado // J Hepatol. – 2015. – Vol.63.
– №1. – P.237-64.57.Erdogan S, Dogan HO, Sezer S, et al. The diagnostic value of non-invasive tests for theevaluation of liver fibrosis in chronic hepatitis B patients // Scand J Clin Lab Invest. – 2013. –Vol.73. – №4. – P.300-308 Mar 20.58.Farkkila M., Rautiainen H., Karkkainen P., et al. Serological markers for monitoring diseaseprogression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy // LiverInt. – 2008. – Vol.28.
– №6. – P.787-97.59.Fierbinteanu Braticevici C., Sporea I., Panaitescu E., Tribus L. Value of acoustic radiationforce impulse imaging elastography for non-invasive evaluation of patients with nonalcoholicfatty liver disease // Ultrasound Med Biol. – 2013. – Vol.39. – №11. – P.1942–1950.60.Fitzpatrick E. and Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease:Current status and a glimpse of the future // World J Gastroenterol. – 2014.
– Vol.20. – №31.– P.10851–10863.61.Floreani A., Cazzagon N., Martines D., Cavalletto L., Baldo V., Chemello L. Performanceand utility of transient elastography and noninvasive markers of liver fibrosis in primarybiliary cirrhosis // Dig Liver Dis. – 2011. – Vol.43. – №11. – P.887-92.62.Forns X., Ampurdanès S., Llovet J.M., Aponte J., Quintó L., Martínez-Bauer E., et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictivemodel // Hepatology. – 2002. – Vol.36. – №4 Pt 1. – P.986-92.63.Friedrich-Rust M., Müller C., Winckler A., Kriener S., Herrmann E., Holtmeier J., PoynardT., et al.
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MRspectroscopy, and serum markers // J Clin Gastroenterol. – 2010. – Vol.44. – №1. – P.58-65.64.Friedrich-Rust M., Nierhoff J., Lupsor M., Sporea I., Fierbinteanu-Braticevici C., Strobel D.,et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liverfibrosis: a pooled meta-analysis // J Viral Hepat. – 2012. Vol.19. – №2 – P.e212–e219.65.Friedrich-Rust M., Romen D., Vermehren J., Kriener S., Sadet D., Herrmann E., et al.Acoustic radiation force impulse-imaging and transient elastography for non-invasiveassessment of liver fibrosis and steatosis in NAFLD // Eur J Radiol.
– 2012. – Vol.81. – №3.– P.e325–e331.66.Friedrich-Rust M., Rosenberg W., Parkes J., et al. Comparison of ELF, FibroTest andFibroScan for the non-invasive assessment of liver fibrosis // BMC Gastroenterol. – 2010. – 134 Vol.10. – №103. – P. 1-8.67.Garrido M. C., Hubscher S. G. Accuracy of staging in primary biliary cirrhosis // J ClinPathol. – 1996. – Vol.49. – P.556-559.68.Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated withan increase in AST/ALT ratio // Dig Dis Sci.
– 1999. – Vol.44. – №6. – P. 1249–53.69.Giannini EG, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasivediagnosis of esophageal varices: results of a multicenter, prospective, validation study // Am JGastroenterol. – 2006. – Vol.101. – №11. – P.2511-9.70.Goertz R.S., Zopf Y., Jugl V., Heide R., Janson C., Strobel D., et al. Measurement of liverelasticity with acoustic radiation force impulse (ARFI) technology: an alternative noninvasivemethod for staging liver fibrosis in viral hepatitis // Ultraschall Med. – 2010. – Vol.31.
– №2– P.151–155.71.Goodman Z.D. Grading and staging systems for inflammation and fibrosis in chronic liverdiseases // J Hepatol. 2007. – Vol.47. – №4. – P.598-607.72.Goyal R., Mallick S.R., Mahanta M., Kedia S., Shalimar, Dhingra R., et al.
Fibroscan canavoid liver biopsy in Indian patients with chronic hepatitis B // J Gastroenterol Hepatol. –2013. – Vol.28. – №11. – P.1738–1745.73.Gressner A., Gao C., Gressner O. Non-invasive biomarkers for monitoring the fibrogenicprocess in liver: A short survey // World J Gastroenterol. – 2009. – Vol.15. – №20. – P. 24332440.74.Guo Y., Parthasarathy S., Goyal P., McCarthy R.J., Larson A.C., Miller F.H. Magneticresonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: ameta-analysis // Abdom Imaging. – 2015. – Vol.40. – №4. – P.818-34.75.Gutkowski K., Hartleb M., Kacperek-Hartleb T., Kajor M., Mazur W., Zych W., et al.Laboratory-based scoring system for prediction of hepatic inflammatory activity in patientswith autoimmune hepatitis // Liver Int. – 2013.
– Vol.33. – №9. – P.1370-7.76.Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operatingcharacteristic curves derived from the same cases // Radiology. – 1983. - Vol. 148. - P. 839843.77.Henderson N.C., Arnold T.D., Katamura Y., Giacomini M.M., Rodriguez J.D., McCarty J.H.,et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis inseveral organs // Nat Med. – 2013. – Vol.19. – №12. – P.1617-24.78.Hernandez-Gea V., Friedman S.L. Pathogenesis of liver fibrosis // Annu Rev Pathol.
– 2011.– Vol.6. – P.425-56.79.Hui A.Y., Friedman S.L. Molecular basis of hepatic fibrosis // Expert Rev Mol Med. – 2003. 135 – Vol.5. – №5. – P.1-23.80.Huwart L., Sempoux C., Vicaut E., Salameh N., Annet L., Danse E., et al. Magneticresonance elastography for the noninvasive staging of liver fibrosis // Gastroenterology. –2008. – Vol.135. – №1. – P.32-40.81.Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T.
Biochemicalmarkers of liver fibrosis in patients with hepatitis C virus infection: a prospective study //Lancet. – 2001. – Vol.357. - №9262. – Р.1069–1075.82.Iredale J.P. Defining therapeutic targets for liver fibrosis: exploiting the biology ofinflammation and repair // Pharmacol. Res. – 2008. – Vol.58. – №2. – P.129–136.83.Kayadibi H., Yasar B., Ozkara S., Serdar M.A., Kurdas O.O., Gonen C.
The diagnosticaccuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosisindex for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis //Scand J Clin Lab Invest. – 2014. – Vol.74. – №3. – P.240-7.84.Kisseleva T., Cong M., Paik Y., Scholten D., Jiang C., Benner C., et al. Myofibroblasts revertto an inactive phenotype during regression of liver fibrosis // Proc Natl Acad Sci U S A. –2012. – Vol.109.
– №24. – P.9448-53.85.Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., et al. Senescenceof activated stellate cells limits liver fibrosis // Cell. – 2008. – Vol.134. – №4. – P.657–66786.Landis J.R., Koch G.G. The measurement of the observer agreement for categorical data //Biometrics. – 1977. –Vol.33. – P.159–174.87.Lee H.H., Seo Y.S., Um S.H., Won N.H., Yoo H., Jung E.S., et al. Usefulness of non-invasivemarkers for predicting significant fibrosis in patients with chronic liver disease // J KoreanMed Sci.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
